HSA-free formulations of interferon-beta

Details HSA-free formulations of interferon-beta HSA-free formulations of interferon-beta

2004-04-09

2008-07-15

Saoud, Christine J. (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C424S085100, C530S351000

Reexamination Certificate

active

07399463

ABSTRACT:
Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-β) and methods useful in their preparation are provided. The compositions comprise the IFN-β solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-β in pharmaceutical compositions, are provided.

REFERENCES:
patent: 4439181 (1984-03-01), Blackshear et al.
patent: 4462940 (1984-07-01), Hanisch et al.
patent: 4465622 (1984-08-01), Nobuhara et al.
patent: 4605555 (1986-08-01), Sato et al.
patent: 4605556 (1986-08-01), Sato et al.
patent: 4647454 (1987-03-01), Cymbalista
patent: 4675184 (1987-06-01), Hasegawa et al.
patent: 5004605 (1991-04-01), Hershenson et al.
patent: 5104651 (1992-04-01), Boone et al.
patent: 5151265 (1992-09-01), Hwang-Felgner et al.
patent: 5183746 (1993-02-01), Shaked et al.
patent: 5609868 (1997-03-01), Lowther et al.
patent: 5643566 (1997-07-01), Hanisch et al.
patent: 5762923 (1998-06-01), Gross et al.
patent: 5763409 (1998-06-01), Bayol et al.
patent: 5814485 (1998-09-01), Dorin et al.
patent: 6525102 (2003-02-01), Chen et al.
patent: 6887462 (2005-05-01), Shirley et al.
patent: 2003/0180253 (2003-09-01), Chen et al.
patent: 2304808 (1997-09-01), None
patent: 0 080 879 (1986-10-01), None
patent: 0 284 249 (1988-09-01), None
patent: 0 164 397 (1990-07-01), None
patent: 0 410 207 (1991-01-01), None
patent: 0 410 207 (1991-01-01), None
patent: 0 133 767 (1991-04-01), None
patent: 0 477 386 (1992-01-01), None
patent: 0 215 658 (1994-06-01), None
patent: 0 736 303 (1996-10-01), None
patent: 0 759 775 (1997-03-01), None
patent: WO 89/02750 (1989-04-01), None
patent: WO 89/05158 (1989-06-01), None
patent: WO 90/06762 (1990-06-01), None
patent: WO 91/16038 (1991-10-01), None
patent: WO 95/31213 (1995-11-01), None
patent: WO 95/31479 (1995-11-01), None
patent: WO 98/28007 (1998-07-01), None
patent: WO 99/15193 (1999-04-01), None
patent: WO 99/51272 (1999-10-01), None
patent: WO 02/34791 (2002-05-01), None
The Merck Index, 1983, p. 121.
Boublik et al., “Conformation and Activity of Recombinant Human Fibroblast Interferon-β,”Journal of Interferon Research, 1990, pp. 213-219, vol. 10.
Utsumi et al., “Stability of Human Interferon-β1: Oligomeric human Interferon- β1 is Inactive But is Reactivated by Monomerization,”Biochimica et Biophysica Acta, 1989, pp. 167-172, vol. 998.
The Merck Index, 1989, p. 859.

Affiliated with

Also associated with

Rating

HSA-free formulations of interferon-beta does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HSA-free formulations of interferon-beta, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HSA-free formulations of interferon-beta will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3971646